BioArctic (Sweden) Alpha and Beta Analysis

BIOA-B Stock  SEK 193.10  5.60  2.99%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as BioArctic AB. It also helps investors analyze the systematic and unsystematic risks associated with investing in BioArctic over a specified time horizon. Remember, high BioArctic's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to BioArctic's market risk premium analysis include:
Beta
0.82
Alpha
0.21
Risk
4.75
Sharpe Ratio
0.074
Expected Return
0.35
Please note that although BioArctic alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, BioArctic did 0.21  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of BioArctic AB stock's relative risk over its benchmark. BioArctic AB has a beta of 0.82  . As returns on the market increase, BioArctic's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioArctic is expected to be smaller as well. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out BioArctic Backtesting, BioArctic Valuation, BioArctic Correlation, BioArctic Hype Analysis, BioArctic Volatility, BioArctic History and analyze BioArctic Performance.

BioArctic Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. BioArctic market risk premium is the additional return an investor will receive from holding BioArctic long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in BioArctic. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate BioArctic's performance over market.
α0.21   β0.82

BioArctic expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of BioArctic's Buy-and-hold return. Our buy-and-hold chart shows how BioArctic performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

BioArctic Market Price Analysis

Market price analysis indicators help investors to evaluate how BioArctic stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioArctic shares will generate the highest return on investment. By understating and applying BioArctic stock market price indicators, traders can identify BioArctic position entry and exit signals to maximize returns.

BioArctic Return and Market Media

The median price of BioArctic for the period between Sun, Sep 1, 2024 and Sat, Nov 30, 2024 is 162.9 with a coefficient of variation of 8.36. The daily time series for the period is distributed with a sample standard deviation of 13.8, arithmetic mean of 164.94, and mean deviation of 10.9. The Stock did not receive any noticable media coverage during the period.
 Price Growth (%)  
       Timeline  

About BioArctic Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including BioArctic or other stocks. Alpha measures the amount that position in BioArctic AB has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioArctic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioArctic's short interest history, or implied volatility extrapolated from BioArctic options trading.

Build Portfolio with BioArctic

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Other Information on Investing in BioArctic Stock

BioArctic financial ratios help investors to determine whether BioArctic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioArctic with respect to the benefits of owning BioArctic security.